Abstract: The present invention relates to Neisseria ORF2086 proteins, crossreactive immunogenic proteins which can be isolated from nesserial strains or prepared recombinantly, including immunogenic portions thereof, biological equivalents thereof, antibodies that immunospecifically bind to the foregoing and nucleic acid sequences encoding each of the foregoing, as well as the use of same in immunogenic compositions that are effective against infection by Neisseria meningitidis serogroup B.
Type:
Application
Filed:
April 25, 2012
Publication date:
November 29, 2012
Applicant:
Wyeth Holdings Corporation
Inventors:
Gary W. Zlotnick, Leah Diane Fletcher, John Erwin Farley, Liesel A. Bernfield, Robert J. Zagursky, Benjamin J. Metcalf
Abstract: The present invention relates to Neisseria ORF2086 proteins, crossreactive immunogenic proteins which can be isolated from nesserial strains or prepared recombinantly, including immunogenic portions thereof, biological equivalents thereof, antibodies that immunospecifically bind to the foregoing and nucleic acid sequences encoding each of the foregoing, as well as the use of same in immunogenic compositions that are effective against infection by Neisseria meningitidis serogroup B.
Type:
Application
Filed:
April 25, 2012
Publication date:
November 22, 2012
Applicant:
Wyeth Holdings Corporation
Inventors:
Gary W. Zlotnick, Leah Diane Fletcher, John Erwin Farley, Liesel A. Bernfield, Robert J. Zagursky, Benjamin J. Metcalf
Abstract: Methods for preparing monomeric cytotoxic drug/carrier conjugates with a drug loading significantly higher than in previously reported procedures and with decreased aggregation and low conjugate fraction (LCF) are described. Cytotoxic drug derivative/antibody conjugates, compositions comprising the conjugates and uses of the conjugates are also described. Monomeric calicheamicin derivative/anti-CD22 antibody conjugates, compositions comprising the conjugates and uses of the conjugates are also described.
Type:
Application
Filed:
February 13, 2012
Publication date:
August 23, 2012
Applicant:
WYETH HOLDINGS CORPORATION
Inventors:
ARTHUR KUNZ, Justin Keith Moran, Joseph Thomas Rubino, Neera Jain, Eugene Joseph Vidunas, John McLean Simpson, Paul David Robbins, Nishith Merchant, John Francis Dijoseph, Mark Edward Ruppen, Nitin Krishnaji Damle, Andrew George Popplewell
Abstract: The invention provides compounds of formula Wherein R1, R2, R3, R4, R5, R6a, R6b, R6c, R6d, R6e and R7 are defined in the specification. These compounds are useful as antibiotic agents.
Type:
Grant
Filed:
February 8, 2011
Date of Patent:
August 21, 2012
Assignees:
American Cyanamid Company, Wyeth Holdings Corporation
Inventors:
Jason Arnold Lotvin, Mark Edward Ruppen
Abstract: The present invention relates to newly identified open reading frames comprised within the genomic nucleotide sequence of Streptococcus pneumoniae, wherein the open reading frames encode polypeptides that are surface localized on Streptococcus pneumoniae. Thus, the invention relates to Streptococcus pneumoniae open reading frames that encode polypeptide antigens, polypeptides, preferably antigenic polypeptides, encoded by the Streptococcus pneumoniae open reading frames, vectors comprising open reading frame sequences and cells or animals transformed with these vectors. The invention relates also to methods of detecting these nucleic acids or polypeptides and kits for diagnosing Streptococcus pneumoniae infection. The invention finally relates to pharmaceutical compositions, in particular immunogenic compositions, for the prevention and/or treatment of bacterial infection, in particular infections with Streptococcus pneumoniae.
Type:
Grant
Filed:
May 12, 2010
Date of Patent:
August 14, 2012
Assignee:
Wyeth Holdings Corporation
Inventors:
Robert John Zagursky, Amy Wadhams Masi, Bruce Arthur Green, Deb Narayan Chakravarti, David Parrish Russell, Joseph Lawrence Wooters
Abstract: The present invention relates to Neisseria ORF2086 proteins, crossreactive immunogenic proteins which can be isolated from nesserial strains or prepared recombinantly, including immunogenic portions thereof, biological equivalents thereof, antibodies that immunospecifically bind to the foregoing and nucleic acid sequences encoding each of the foregoing, as well as the use of same in immunogenic compositions that are effective against infection by Neisseria meningitidis serogroup B.
Type:
Application
Filed:
December 21, 2011
Publication date:
August 9, 2012
Applicant:
Wyeth Holdings Corporation
Inventors:
Gary W. ZLOTNICK, Leah Diane FLETCHER, John Erwin Farley, Liesel A. BERNFIELD, Robert J. ZAGURSKY, Benjamin J. METCALF
Abstract: Methods for preparing monomeric cytotoxic drug/carrier conjugates with a drug loading significantly higher than in previously reported procedures and with decreased aggregation and low conjugate fraction (LCF) are described. Cytotoxic drug derivative/antibody conjugates, compositions comprising the conjugates and uses of the conjugates are also described. Monomeric calicheamicin derivative/anti-CD22 antibody conjugates, compositions comprising the conjugates and uses of the conjugates are also described.
Type:
Grant
Filed:
May 2, 2003
Date of Patent:
April 10, 2012
Assignee:
Wyeth Holdings Corporation
Inventors:
Arthur Kunz, Justin Keith Moran, Joseph Thomas Rubino, Neera Jain, Eugene Joseph Vidunas, John McLean Simpson, Paul David Robbins, Nishith Merchant, John Francis DiJoseph, Mark Edward Ruppen, Nitin Krishnaji Damle, Andrew George Popplewell
Abstract: The present invention relates to Neisseria ORF2086 proteins, crossreactive immunogenic proteins which can be isolated from nesserial strains or prepared recombinantly, including immunogenic portions thereof, biological equivalents thereof, antibodies that immunospecifically bind to the foregoing and nucleic acid sequences encoding each of the foregoing, as well as the use of same in immunogenic compositions that are effective against infection by Neisseria meningitidis serogroup B.
Type:
Application
Filed:
March 20, 2009
Publication date:
February 9, 2012
Applicant:
Wyeth Holdings Corporation
Inventors:
Gary W. Zlotnick, Leah Diane Fletcher, John Erwin Farley, Liesel A. Bernfield, Robert J. Zagursky, Benjamin J. Metcalf
Abstract: The invention provides compounds of formula Wherein R1, R2, R3, R4, R5, R6a, R6b, R6c, R6d, R6e and R7 are defined in the specification. These compounds are useful as antibiotic agents.
Type:
Application
Filed:
February 8, 2011
Publication date:
June 23, 2011
Applicants:
AMERICAN CYANAMID COMPANY, Wyeth Holdings Corporation
Inventors:
Jason Arnold Lotvin, Mark Edward Ruppen
Abstract: The present invention relates to Neisseria ORF2086 proteins, crossreactive immunogenic proteins which can be isolated from nesserial strains or prepared recombinantly, including immunogenic portions thereof, biological equivalents thereof, antibodies that immunospecifically bind to the foregoing and nucleic acid sequences encoding each of the foregoing, as well as the use of same in immunogenic compositions that are effective against infection by Neisseria meningitidis serogroup B.
Type:
Application
Filed:
March 20, 2009
Publication date:
March 31, 2011
Applicant:
WYETH HOLDINGS CORPORATION
Inventors:
Gary W. Zlotnick, Leah Diane Fletcher, John Erwin Farley, Liesel A. Bernfield, Robert J. Zagursky, Benjamin J. Metcalf
Abstract: This invention relates to methods for treating or inhibiting cancers in a mammal in need thereof, which comprises administering an effective amount of a 6-Aryl-7-halo-imidazo[1,2 -a]pyrimidine compound of the formula: or pharmaceutically acceptable salts thereof.
Abstract: An aminocarboxylic acid chelating agent, preferably EDTA, or a salt thereof has been found to be useful for inhibiting particulate formation in piperacillin/tazobactam parenteral combinations. The composition may also contain a buffer, preferably citrate, and optionally an aminoglycoside. The product may be in the form of a frozen composition that can be thawed for use. The product may also be in the form of a cryodesiccated powder that can be reconstituted by addition of an aqueous vehicle to reform a solution.
Type:
Grant
Filed:
February 13, 2009
Date of Patent:
March 29, 2011
Assignee:
Wyeth Holdings Corporation
Inventors:
Jonathan Marc Cohen, Syed Muzafar Shah, Christian Luther Ofslager, Mahdi Bakir Fawzi
Abstract: Compositions and methods for treating Severe Acute Respiratory Syndrome (SARS) are disclosed herein. Inhibitors of SARS-associated inflammatory cytokines are provided herein for use in treating SARS, including SARS-associated coronavirus (SARS-CoV) infection. Inhibitors of TNF are disclosed herein, as is the use of said inhibitors for treating SARS, including SARS-CoV. Methods of identifying and screening for said inhibitors are also provided.
Abstract: The present invention relates to the purification of polypeptides and the removal of endotoxin via immobilized metal affinity chromatography (IMAC). More specifically, the invention relates to methods for removing bacterial endotoxin in a protein solution. In specific embodiments, the invention relates to the elimination of endotoxin from Moraxella catarrhalis outer membrane proteins.
Type:
Grant
Filed:
March 23, 2005
Date of Patent:
November 30, 2010
Assignee:
Wyeth Holdings Corporation
Inventors:
Rhonda Lunt Sundberg, Robert Leonard Hopfer
Abstract: The use of 3-O-deacylated monophosphoryl lipid A or monophosphoryl lipid A and derivatives and analogs thereof, in combination with a cytokine or lymphokine such as granulocyte macrophage colony stimulating factor or interleukin-12 is useful as an adjuvant combination in an antigenic composition to enhance the immune response in a vertebrate host to a selected antigen.
Abstract: The present invention relates to newly identified open reading frames comprised within the genomic nucleotide sequence of Streptococcus pneumoniae, wherein the open reading frames encode polypeptides that are surface localized on Streptococcus pneumoniae. Thus, the invention relates to Streptococcus pneumoniae open reading frames that encode polypeptide antigens, polypeptides, preferably antigenic polypeptides, encoded by the Streptococcus pneumoniae open reading frames, vectors comprising open reading frame sequences and cells or animals transformed with these vectors. The invention relates also to methods of detecting these nucleic acids or polypeptides and kits for diagnosing Streptococcus pneumoniae infection. The invention finally relates to pharmaceutical compositions, in particular immunogenic compositions, for the prevention and/or treatment of bacterial infection, in particular infections with Streptococcus pneumoniae.
Type:
Application
Filed:
May 12, 2010
Publication date:
September 2, 2010
Applicant:
WYETH HOLDINGS CORPORATION
Inventors:
ROBERT JOHN ZAGURSKY, AMY WADHAMS MASI, BRUCE ARTHUR GREEN, DEB NARAYAN CHAKRAVARTI, DAVID PARRISH RUSSELL, JOSEPH LAWRENCE WOOTERS
Abstract: The present invention relates to Neisseria ORF2086 proteins, crossreactive immunogenic proteins which can be isolated from nesserial strains or prepared recombinantly, including immunogenic portions thereof, biological equivalents thereof, antibodies that immunospecifically bind to the foregoing and nucleic acid sequences encoding each of the foregoing, as well as the use of same in immunogenic compositions that are effective against infection by Neisseria meningitidis serogroup B.
Type:
Grant
Filed:
September 2, 2003
Date of Patent:
August 31, 2010
Assignee:
Wyeth Holdings Corporation
Inventors:
Gary W. Zlotnick, Leah Diane Fletcher, John Erwin Farley, Liesel A. Bernfield, Robert J. Zagursky, Benjamin J. Metcalf
Abstract: The expression of the lipidated form of the peptidoglycan-associated protein (PAL) of gram-negative bacteria is achieved through the use of a plasmid containing a tightly regulated promoter. A bacterial host cell is transformed, transduced or transfected with such a plasmid. The host cell is then cultured under conditions such that the lipidated recombinant PAL is expressed. The lipidated recombinant PAL is included in an antigenic composition administered to a mammalian host to immunize against a gram-negative bacterium.
Abstract: A process for producing isolated and purified respiratory syncytial virus (RSV) fusion (F) and attachment (G) glycoproteins in eukaryotic cell cultures infected with RSV cold-passaged, temperature-sensitive mutant subgroup A2 strain cpts-248/404 results in at least a 5-fold increase in F and G protein yields when compared with the parent A2 strain. Immunogenic compositions comprising the F and/or G protein(s) produced by this process can be formulated for in vivo administration to a host to confer protection against disease caused by RSV.
Type:
Grant
Filed:
March 17, 2004
Date of Patent:
March 30, 2010
Assignee:
Wyeth Holdings Corporation
Inventors:
Firelli Alonso-Caplen, Mark Cutler, Mirelli Fino, Earl Pursell, Robert Repetto
Abstract: This invention provides compounds of formula I having the structure wherein G1, G2, R1, R4, Z, n, and X are defined in the specification or a pharmaceutically acceptable salt thereof which are useful as antineoplastic agents and in the treatment of polycystic kidney disease.
Type:
Grant
Filed:
May 21, 2010
Date of Patent:
May 17, 2011
Assignee:
Wyeth Holdings Corporation
Inventors:
Allan Wissner, Hwei-Ru Tsou, Dan M. Berger, Middleton B. Floyd, Jr., Philip R. Hamann, Nan Zhang, Philip Frost